Macroeconomic forces can only carry the sector so far, though. Innovative new drugs, and the study data that supports them, are what sustains investors’ attention.
A group of imminent clinical trial readouts, then, could either speed or stall any biotech momentum. Here are 10 to watch:
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,